Use of adjunctive antipsychotic medications in depression

March 12, 2013

A study published this week in PLOS Medicine finds that while antipsychotic medications are associated with small-to-moderate improvements in depressive symptoms in adults, there is little evidence for improvement on measures of quality of life and these medications are linked to adverse events such as weight gain and sedation.

The results of the study, conducted by Glen Spielmans of Metropolitan State University in St. Paul, Minnesota and colleagues, have potential implications for the treatment of depression by providing clinicians with a better understanding of the risk–benefit profiles for commonly prescribed .

The authors reached these conclusions by combining the results from 14 published or unpublished randomized clinical trials (duration 4-12 weeks) comparing an adjunctive antipsychotic medication (, /fluoxetine combination [OFC], , or ) to placebo in the treatment of depression that had not responded to antidepressant medication alone.

The four medications showed statistically significant small or small-to-moderate beneficial effects on . However, on measures of functioning and quality of life, these medications generally produced either no benefit or small benefits. In addition, treatment was linked to several adverse events, such as akathisia, sedation, abnormal metabolic laboratory results, and weight gain. The authors also comment that shortcomings in study design and reporting may have over-emphasized the apparent benefits of treatment and reduced the apparent incidence of adverse events.

The authors say: "Taken together, our meta-analysis found evidence of (1) some improvement in clinician-assessed depressive symptoms, (2) little evidence of substantial benefit in overall well-being, and (3) abundant evidence of potential treatment-related harm."

They add: "Our comprehensive evaluation of safety and both relative and absolute efficacy provides critical insight that may be useful for clinicians attempting to thoroughly understand the risk–benefit profiles of these adjunctive treatments for major depressive disorder."

Individuals treated with adjunctive antipsychotic medication who are concerned about potential side effects are urged to discuss this study with their physician before making any decisions to stop taking or change any medications.

Explore further: Atypical antipsychotics may aid symptons for some off-label uses, but not others

More information: Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, et al. (2013) Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes. PLoS Med 10(3): e1001403. doi:10.1371/journal.pmed.1001403

Related Stories

Atypical antipsychotics may aid symptons for some off-label uses, but not others

September 27, 2011
Medical evidence suggests that psychiatric drugs known as atypical antipsychotics are effective in reducing symptoms for some off-label conditions, but not others, according to a new RAND Corporation study.

Use of antipsychotics for reducing military-related chronic PTSD symptoms does not appear effective

August 2, 2011
Patients with military-related, chronic posttraumatic stress disorder (PTSD) and symptoms that were not improved with use of an antidepressant medication did not experience a reduction in PTSD symptoms with use of the antipsychotic ...

Reducing off-label use of antipsychotic medications may save money

May 15, 2012
Reducing the non-FDA-approved use of antipsychotic drugs may be a way to save money while having little effect on patient care, according to a Penn State College of Medicine study.

Recommended for you

Neuroticism may postpone death for some

July 24, 2017
Data from a longitudinal study of over 500,000 people in the United Kingdom indicate that having higher levels of the personality trait neuroticism may reduce the risk of death for individuals who report being in fair or ...

Study examines effects of stopping psychiatric medication

July 20, 2017
Despite numerous obstacles and severe withdrawal effects, long-term users of psychiatric drugs can stop taking them if they choose, and mental health care professionals could be more helpful to such individuals, according ...

Study finds gene variant increases risk for depression

July 20, 2017
A University of Central Florida study has found that a gene variant, thought to be carried by nearly 25 percent of the population, increases the odds of developing depression.

In making decisions, are you an ant or a grasshopper?

July 20, 2017
In one of Aesop's famous fables, we are introduced to the grasshopper and the ant, whose decisions about how to spend their time affect their lives and future. The jovial grasshopper has a blast all summer singing and playing, ...

Perceiving oneself as less physically active than peers is linked to a shorter lifespan

July 20, 2017
Would you say that you are physically more active, less active, or about equally active as other people your age?

Old antibiotic could form new depression treatment

July 19, 2017
An antibiotic used mostly to treat acne has been found to improve the quality of life for people with major depression, in a world-first clinical trial conducted at Deakin University.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.